Your Trusted Brand for Over 35 Years

Cervical Dysplasia References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Nicol AF, Fernandez AT, et al. Immune response in cervical dysplasia induced by human papillomavirus: The influence of human immunodeficiency virus-1 co-infection—review. MemInstOswaldo Cruz. 2005 Feb;100(1):1-12
  2. Marshall K. Cervical dysplasia: Early intervention. Altern Med Rev. 2003 May;8(2):156-70.
  3. Rock CL, Michael CW, et al. Prevention of cervix cancer. Crit Rev OncolHematol. 2000 Mar;33(3):169-85.
  4. Potischman N, Brinton LA. Nutrition and cervical neoplasia. Cancer Causes Control. 1996 Jan;7(1):113-26.
  5. Giuliano AR, Gapstur S. Can cervical dysplasia and cancer be prevented with nutrients? Nutr Rev. 1998 Jan;56(1 Pt 1):9-16.
  6. Yeo AS , Schiff MA, et al. Serum micronutrients and cervical dysplasia in Southwestern American Indian women. Nutr Cancer . 2000;38(2):141-50.
  7. BekkersRL, Massuger LF, et al. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Rev Med Virol. 2004 Mar-Apr;14(2):95-105.
  8. Liu T, Soong SJ, et al. A case control study of nutritional factors and cervical dysplasia. Cancer Epidemiol Biomarkers Prev. 1993 Nov-Dec;2(6):525-30.
  9. Wright TC, Cox JT. Human papillomaviruses natural history of infections. In: Clinical Uses for Human Papillomavirus (HPV) DNA Testing. American Society for Colposcopy and Cervical Pathology 2004.
  10. Pereira DB, Antoni MH, et al. Inhibited interpersonal coping style predicts poorer adherence to scheduled clinic visits in human immunodeficiency virus infected women at risk for cervical cancer. Ann Behav Med. 2004 Dec;28(3):195-202.
  11. Maissi E, Marteau TM, et al. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: Cross sectional questionnaire study. BMJ. 2004 May 29;328(7451):1293.
  12. Holowaty P, Miller AB, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999 Feb 3;91(3):252-8.
  13. ArendsMJ, Buckley CH, et al. Aetiology, pathogenesis, and pathology of cervical neoplasia. J ClinPathol. 1998 Feb;51(2):96-103.
  14. McIndoe WA , McLean MR, et al. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol. 1984 Oct;64(4):451-8.
  15. Jones BA, Davey DD. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med. 2000 May;124(5):672-81.
  16. Shinn E, Basen-Engquist K, et al. Distress after an abnormal Pap smear result: Scale development and psychometric validation. Prev Med. 2004 Aug;39(2):404-12.
  17. Bornstein J, Bahat-Sterensus H. Predictive factors for noncompliance with follow-up among women treated for cervical intraepithelial neoplasia. GynecolObstet Invest. 2004;58(4):202-6.
  18. Fowler BM, Giuliano AR , et al. Hypomethylation in cervical tissue: Is there a correlation with folate status? Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):901-906.
  19. Goodman MT, McDuffie K, et al. Association of methylenetetrahydrofolatereductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1275-80.
  20. Ho GY, Palan PR, et al. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer. 1998 Nov 23;78(5):594-9.
  21. Li SM, Zhang WH, et al. Preliminary study on the relationship between loads of human papillomavirus in cervical carcinoma and cervical intraepithelial neoplasia. Zhonghua Fu Chan KeZaZhi. 2004 Jun;36(6):400-2.
  22. Schlecht NF , Trevisan A, et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer. 2003 Feb 10;103(4):519-24.
  23. Dalstein V, Riethmuller D, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: A longitudinal French cohort study. Int J Cancer. 2003 Sep 1;106(3):396-403.
  24. Ylitalo N, Sorensen P, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet. 2000 Jun 24;355(9222):2194-8.
  25. Josefsson AM, Magnusson PK, et al. Viral of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study. Lancet. 2000 Jun 24;355(9222):2189-93.
  26. Romney SL, Ho GY, et al. Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. GynecolOncol. 1997 Jun;65(3):483-92.
  27. Flores R, Papenfuss M, et al. Cross-sectional analysis of oncogenic HPV viral load and cervical intraepithelial neoplasia. Int J Cancer. 2005 Sep 8 (Epub ahead of print).
  28. Thomson SW, Heimburger DC, et al. Effect of total plasma homocysteine on cervical dysplasia risk. Nutr Cancer. 2000;37(2):128-33.
  29. Liu T, Soong SJ, et al. A longitudinal analysis of human papillomavirus 16 infection, nutritional status, and cervical dysplasia progression. Cancer Epidemiol Biomarkers Prev. 1995 Jun;4(4):373-80.
  30. Giuliano AR, Papenfuss M, et al. Antioxidant nutrients: Associations with persistent human papillomavirus infection. Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):917-23.
  31. Palan PR, Mikhail MS, et al. Plasma levels of antioxidant beta-carotene and alpha-tocopherol in uterine cervix dysplasias and cancer. Nutr Cancer. 1991;15(1):13-20.
  32. Tay SK, Tay KJ. Passive cigarette smoking is a risk factor in cervical neoplasia. GynecolOncol. 2004 Apr;93(1):116-20.
  33. Wee CC, McCarthy EP, et al. Screening for cervical and breast cancer: Is obesity an unrecognized barrier to preventive care? Ann Intern Med. 2000 May 2;132(9):697-704.
  34. Munoz N, Franseschi S, et al. Role of parity and human papillomavirus in cervical cancer: The IARCmulticentric case-control study. Lancet. 2002 Mar 30;359(9312):1093-1101.
  35. Centers for Disease Control Web site. Available at: Accessed October 20, 2005.
  36. Duerr A, Kieke B, et al. Human papillomavirus-associated cervical cytologic abnormalities among women with or at risk of infection with immunodeficiency virus. Am J Obstet Gynecol. 2001 Mar;184(4):584-90.
  37. Robinson WR, Andersen J, et al. Isotretinoin for low-grade cervical dysplasia in human immunodeficiency virus-infected women. Obstet Gynecol. 2002 May;99(5 Pt 1):777-84.
  38. Bernatsky S, Ramsey-Goldman R, et al. Factors associated with abnormal Pap results in systemic lupus erythematosus. Rheumatology (Oxford). 2004 Nov;43(11):1386-9.
  39. Malouf MA, Hopkins PM, et al. Sexual health issues after lung transplantation: Importance of cervical screening. J Heart Lung Transplant. 2004 Jul;23(7):894-7.
  40. Ozsaran AA, Ates T, et al. Evaluation of the risk of cervical intraepithelial neoplasia and human papillomavirus infection in renal transplant patients receiving immunosuppressive therapy. Eur J GynaecolOncol. 1999;20(2):127-30.
  41. Smith JS, Herrero R, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst. 2002a Nov 6;94(21):1604-13.
  42. Smith JS, Munoz N, et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis . 2002b Feb 1;185(3):324-31.
  43. Castle PE, Escoffery C, et al. Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotrophic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients. Sex Trans Dis. 2003 Jul;30(7):575-80.
  44. Tran-Thanh D, Provencher D, et al. Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix. Am J Obstet Gynecol. 2003 Jan;188(1):129-34.
  45. Aschkenazi-Steinberg SO, Spitzer BJ, et al. The role treatment for cervical intraepithelial neoplasia plays in the disappearance of human papilloma virus. J Low Genit Tract Dis. 2005 Jan;9(1):19-22.
  46. Das N, Naik R, et al. Recurrent smear abnormalities where repeat loop treatment is not possible: Is hysterectomy the answer? GynecolOncol. 2005 Jun;97(3):751-4.
  47. Stanley MA . Progress in prophylactic and therapeutic vaccines for human papillomavirus infection. Expert Rev Vaccines. 2003aJun;2(3):381-9. Review.
  48. Villa LL. Prophylactic HPV vaccines: Reducing the burden of HPV-related diseases. Vaccine. 2005 Sep 26 (Epub ahead of print).
  49. Torrens I, Mendoza O, et al. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine. 2005 Aug 17 (Epub ahead of print).
  50. Maclean J, Rybicki EP, et al. Vaccination strategies for the prevention of cervical cancer. Expert Rev Anticancer Ther. 2005 Feb;5(1):97-107.
  51. Romney SL, Palan PR, et al. Retinoids and the prevention of cervical dysplasias. Am J Obstet Gynecol. 1981 Dec 15;141(8):890-4.
  52. Wassertheil-Smoller S, Romney SL, et al. Dietary vitamin C and uterine cervical dysplasia. Am J Epidemiol. 1981 Nov;114(5):714-24.
  53. Gagandeep, Dhanalakshmi S, et al. Chemopreventive effects of Cuminumcyminum in chemically induced forestomach and uterine cervix tumors in murine model systems. Nutr Cancer. 2003;47(2):171-80.
  54. Friedman M, Lee KR, et al. Anticarcinogenic effects of glycoalkaloids from potatoes against human cervical, liver, lymphoma, and stomach cancer cells, J Agric Food Chem. 2005 Jul 27;53(15):6162-9.
  55. Kwasniewska A, Tukendorf A. Level of retinol in blood serum of women infected with HPV and with dysplastic changes of the cervix. Med DoswMikrobiol. 1996a;48(1-2):71-7.
  56. Shannon J, Thomas DB, et al. Dietary risk factors for invasive and in-situ cervical carcinomas in Bangkok, Thailand. Cancer Causes Control. 2002 Oct;13(8):691-9.
  57. Volz J, van Rissenbeck A, et al. Changes in the vitamin A status in dysplastic epithelium of the cervix. ZentralblGynakol. 1995;117(9):472-5.
  58. French AL, Kirstein LM, et al. Association of vitamin A deficiency with cervical squamous intraepithelial lesions in human-immunodeficiency virus-infected women. J Infect Dis. 2000 Oct;182(4):1084-9.
  59. Kanetsky PA, Gammon MD, Mandelblatt J, et al. Dietary intake and blood levels of lycopene: association with cervical dysplasia among non-Hispanic, black women. Nutr Cancer. 1998;31(1):31-40.
  60. Nagata C, Shimizu H, et al. Serum retinol level and risk of subsequent cervical cancer in cases with cervical dysplasia. Cancer Invest. 1999;17(4):253-8.
  61. Wylie-Rosett JA, Romney SL, et al. Influence of vitamin A on cervical dysplasia and carcinoma in situ. Nutr Cancer. 1984;6(1):49-57.
  62. Hernandez BY, McDuffie K, et al. Diet and premalignant lesions of the cervix: Evidence of a protective role for folate, riboflavin, thiamin, and vitamin B12. Cancer Causes Control. 2003 Nov;14(9):859-70.
  63. RamaswamyPJ, Natarajan R. Vitamin B6 status in patients with cancer of the uterine cervix. Nutr Cancer. 1984;6(3):176-80.
  64. SedjoRL, Inserra P, et al. Human papillomavirus persistence and nutrients involved in the methylation pathway among a cohort of young women. Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):353-9.
  65. SedjoRL, Fowler BM, et al. Folate, vitamin B12, and homocysteine status: Findings of no relation between human papillomavirus persistence and cervical dysplasia. Nutrition. 2003 Jun;19(6):839-46.
  66. Kwanbunjan K, Saengkar P, et al. Folate status of Thai women cervical dysplasia. Asia Pac J ClinNutr. 2004;13(Suppl):S171.
  67. Buckley DI, McPherson RS, et al. Dietary micronutrients and cervical dysplasia in southwestern American Indian women. Nutr Cancer. 1992;17(2):179-85.
  68. Grio R, Placentino R, et al. Antineoblastic activity of antioxidant vitamins: The role of folic acid in the prevention of cervical dysplasia. Panminerva Med. 1993 Dec;35(4):193-6.
  69. Kwasniewska A, Tukendorf A, et al. Folate deficiency and cervical intraepithelial neoplasia. Eur J GynaecolOncol. 1997;18(6):526-30.
  70. Weinstein SJ, Ziegler RG, et al. Low serum and red blood cell folate are moderately, but nonsignificantly associated with increased risk of invasive cervical cancer in U.S. women. J Nutr. 2001 Jul;131(7):2040-8.
  71. Butterworth CE Jr, Hatch KD, et al. Oral folic acid supplementation for cervical dysplasia: A clinical intervention trial. Am J Obstet Gynecol. 1992 Mar;166(3):803-9.
  72. Ziegler RG. Epidemiological studies of vitamins and cancer of the lung, esophagus, and cervix. AdvExp Med Biol. 1986;206:11-26.
  73. Zarcone R, Bellini P, et al. Folic acid and cervix dysplasia. Minerva Ginecol. 1996 Oct;48(10):397-400.
  74. Butterworth CE Jr, Hatch KD, et al. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. Am J ClinNutr. 1982 Jan;35(1):73-82.
  75. Potischman N, Brinton LA, et al. A case-control study of serum folate levels and invasive cervical cancer. Cancer Res. 1991 Sep 15;51(18):4785-9.
  76. Piyathilake CJ, Macaluso M, et al. Methylenetetrahydrofolatereductase (MTHFR) polymorphism increases the risk of cervical intraepithelial neoplasia. Anticancer Res . 2000 May-Jun;20(3A):1751-7.
  77. Christensen B. Folate deficiency, cancer and congenital abnormalities. Is there a connection? Tidsskr Nor Laegeforen. 1996 Jan 20;116(2):250-4.
  78. Romney SL, Duttagupta S, et al. Plasma vitamin C and uterine cervical dysplasia. Am J Obstet Gynecol. 1985 Apr 1;151(7):976-80.
  79. Palan PR, Mikhail MS, et al. Plasma levels of beta-carotene, lycopene, canthaxanthin, retinol, and alpha- and tau-tocopherol in cervical intraepithelial neoplasia and cancer. Clin Cancer Res. 1996 Jan;2(1):181-5.
  80. Kwasniewska A, Charzewska J, et al. Dietary factors in women with dysplasia colli uteri associated with human papillomavirus infection. Nutr Cancer. 1998;30(1):39-45.
  81. De Vet HC, Knipschild PG, et al. The role of beta-carotene and other dietary factors in the aetiology of cervical dysplasia: Results of a case-control study. Int J Epidemiol. 1991 Sep;20(3):603-10.
  82. Kwasniewska A, Tukendorf A, et al. Frequency of HPV infection and the level of ascorbic acid in serum of women with cervix dysplasia. Med DoswMikrobiol. 1996b;48(3-4):183-8.
  83. Lee GJ, Chung HW, et al. Antioxidant vitamins and lipid peroxidation in patients with cervical intraepithelial neoplasia. J Korean Med Sci. 2005 Apr;20(2):267-72.
  84. Palan PR, Mikhail MS, et al. Plasma concentrations of coenzyme Q10 and tocopherols in cervical intraepithelial neoplasia and cervical cancer. Eur J Cancer Prev. 2003 Aug;12(4):321-6.
  85. Palan PR, Woodall AL, et al. Alpha-tocopherol and alpha-tocopherolquinone levels in cervical intraepithelial neoplasia and cervical cancer. Am J Obstet Gynecol. 2004 May;190(5):1407-10.
  86. Kim SY, KoYS, et al. Changes in lipid peroxidation and antioxidant trace elements in serum of women with cervical intraepithelial neoplasia and invasive cancer. Nutr Cancer. 2003;47(2):126-30.
  87. Goodman MT, Kiviat N, et al. The association of plasma micronutrients with the risk of cervical dysplasia in Hawaii . Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):537-44.
  88. Grail A, Norval M. Copper and zinc levels in serum from patients with abnormalities of the uterine cervix. ActaObstetGynecol Scand. 1986;65(5):443-7.
  89. Rybnikov VI. Trace element content in the blood and tissues of patients with precancerous and precursor diseases of the female genitalia. VoprOnkol. 1985;31(3):18-21.
  90. Amburgey CF, VanEenwyk J, et al. Undernutrition as a risk factor for cervical intraepithelial neoplasia: A case-control analysis. Nutr Cancer. 1993;20(1):51-60.
  91. AnisimovVN, Zabezhinski MA, et al. Inhibitory effect of melatonin on 7,12-dimethylbenz(a)anthracene-induced carcinogenesis of the uterine cervix and vagina in mice and mutagenesis in vitro. Cancer Lett. 2000 Aug 11;156(2):199-205.
  92. Panzer A, Lottering ML, et al. Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells. Cancer Lett. 1998 Jan 9;122(1-2):17-23.
  93. Greenlee H, White E, et al. Supplement use among cancer survivors in the Vitamins and Lifestyle (VITAL) study cohort. J Altern Complement Med. 2004 Aug;10(4):660-6.
  94. Chen LD, Leal BZ, et al. Melatonin's inhibitory effect on growth of ME-180 human cervical cancer cells is not related to intracellular glutathione concentrations. Cancer Lett. 1995 May 8;91(2):153-9.
  95. Karasek M, Kowalski AJ, et al. Serum melatonin circadian profile in women suffering from the genital tract cancers. NeuroEndocrinolLett. 2000;21(2):109-13.
  96. Vlastos AT, Schottenfeld D, et al. Biomarkers and their use in cervical cancer chemoprevention. Crit Rev OncolHematol. 2003 Jun;46(3):261-73.
  97. Stanley M. Chapter 17: Genital human papillomavirus infections--current and prospective therapies. J Natl Cancer InstMonogr. 2003b;(31):117-24. Review.
  98. Bell MC, Crowley-Nowick P, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. GynecolOncol. 2000 Aug;78(2):123-9.
  99. SepkovicDW, Bradlow HL, et al. Quantitative determination of 3,3'-diinolylmethane in urine of individuals receiving indole-3-carbinol. Nutr Cancer. 2001;41(1-2):57-63.
  100. Comerci JT Jr, Runowicz CD, et al. Induction of transforming growth factor beta-1 in cervical intraepithelial neoplasia in vivo after treatment with beta-carotene. Clin Cancer Res. 1997 Feb;3(2):157-60.
  101. AhnWS, Lee JM, et al. Effect of retinoic acid on HPV titration and colposcopic changes in Korean patients with dysplasia of the uterine cervix. J Cell Biochem Suppl. 1997;28-29:133-9.
  102. Darwiche N, Celli G, et al. Specificity of retinoid receptor gene expression in mouse cervical epithelia. Endocrinology. 1994 May;134(5):2018-25.
  103. AhnWS, Yoo J, et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev. 2003 Oct;12(5):383-90.
  104. Wedge DE, Meepagala KM, Magee JB, et al. Anticarcinogenic Activity of Strawberry, Blueberry, and Raspberry Extracts to Breast and Cervical Cancer Cells. J Med Food. 2001;4(1):49-51.
  105. Nagai S, Kurimoto M, et al. Inhibition of cellular proliferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines. J Neurooncol. 2005 Sep;74(2):105-11.
  106. Chen A, Xu J, et al. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through the activity of the transcription factor Egr-1. Oncogene. 2005 Sep 19 (Epub ahead of print).
  107. Ramachandran C, Rodriguez S, et al. Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines. Anticancer Res. 2005 Sep-Oct;25(5):3293-3302.
  108. Sharma RA, GescherAJ, et al. Curcumin: The story so far. Eur J Cancer. 2005 Sep;41(13):1955-68.
  109. SeoWG, Hwang JC, et al. Suppressive effect of Zedoariaerhizoma on pulmonary metastasis of B16 melanoma cells. J Ethnopharmacol. 2005 Oct 3;101(1-3):249-57.
  110. Fang J, Lu J, et al. Thioredoxinreductase is irreversibly modified by curcumin: A novel molecular mechanism for its anticancer ability. J Biol Chem. 2005 Jul 1;280(26):25284-90.
  111. Weber WM, Hunsaker LA, et al. Anti-oxidant activities of curcumin and related enomes. Bioorg Med Chem. 2005 Jun 1;13(11):3811-20.
  112. Karunagaran D, Rashmi R, et al. Induction of apoptosis by curcumin and its implications for cancer therapy. Curr Cancer Drug Targets. 2005 Mar;5(2):117-29.
  113. Furness MS, Robinson TP, et al. Antiangiogenic agents: Studies on fumagillin and curcumin analogs. Curr Pharm Des. 2005;11(3):357-73.
  114. TilakJC, Banerjee M, et al. Antioxidant availability of turmeric in relation to its medicinal and culinary uses. Phytother Res. 2004 Oct;18(10):798-804.
  115. SurhYJ. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res. 1999 Jul 16;428(1-2):305-27.
  116. PrustyBK, Das BC . Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus HPV transcription and AP-1 activity in HeLa cells by curcumin. Int J Cancer. 2005 Mar 1;113(6):951-60.
  117. Limtrakul P, Anuchapreeda S, et al. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer. 2004 Apr 17;4:13.
  118. Chearwae W, Anuchapreeda S, et al. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. BiochemPharmacol. 2004 Nov 15;68(10):2043-52.